Wednesday, 18 March 2026
  
Login

Australia's most trusted
source of pharma news

Wednesday, 18 March 2026
News

'Bad juju' crashes Aussie company

Posted 18 March 2026 PM

Sydney-based Immutep has suffered a severe setback, opting to discontinue a phase 3 trial of its flagship product Eftilagimod Alfa due to futility.

It comes just three months after the company signed an exclusive licensing deal for the first-in-class immunotherapy hopeful, which would have amounted to more than half-a-billion-dollars if all milestones had been met.

To see the whole article, please login


Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.